Skip to content
Company Terminals IPO Intel Calculators Gold Desk Research Services Roadmap Pricing Get started →
The $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focusThe $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focus

Apollo Hospitals Enterprise

APOLLOHOSP · Healthcare Services & Organized Pharmacy Retail · INE437A01024

Analyst mean 1.74 · 27 analysts · 93% bullish
₹8,836.00
Close 2026-09-01 · Moderate risk
Price
₹8,836.00
Mkt cap
₹1.27L cr
P/E (TTM)
59.7xexcl. exceptional items
P/B
13.40x
Book value
₹658.3
ROE
18.1%
Op margin
11.7%
Net margin
8.1%
D/E
0.90
Div yield
0.23%
Consolidatedstandalone figures are read separately and never mixed into these tables
In thirty seconds

Worth watching

0 serious 5 watch 6 findings

Apollo Hospitals (AHEL) is navigating a massive strategic and structural transformation. Its core hospital segment continues to generate solid cash flows (2855.70 crore consolidated CFO in FY2026) with healthy 25.5% operating margins, which are actively being reinvested in a massive 8,000-bed network expansion program. However, this growth is temporarily masked by pre-operating EBITDA drags from recently soft-commissioned hospital beds and the incubation losses of its digital platform, Apollo 24/7. To unlock shareholder value, management is executing a complex series of transactions, including buying out IFC's minority stake in Apollo Health and Lifestyle Limited (AHLL) for 1250.00 crore, combining its capital-intensive Cradle/Fertility business with Cloudnine at an attractive 1550.00 crore valuation (35x EBITDA), and prepping the consolidated HealthCo vertical for a listing as Apollo Healthtech Limited by Q4 FY27. This demerger should decouple the highly profitable brick-and-mortar hospital operations from the high-growth, cash-burning digital and retail pharmacy assets.

  1. Balance-Sheet Cash Depletion on IFC Buyout 1250.00 crore cash deployment from Healthcare Services balance sheet in Q4 FY26 to buy out IFC's minority stake in AHLL, shifting group from sequential net cash to net debt by nearly 1200.00 crore.
  2. Pre-Operating EBITDA Drag from Staggered Launches 41.00 crore EBITDA loss in Q4 FY26 from soft-commissioned hospital beds in Kolkata, Hyderabad, Pune, and Delhi NCR, with cumulative pre-operating losses capped at 150.00 crore for FY2027.
  3. AMSHL Land Lease Non-Renewal Risk Right-of-use assets and lease liabilities adjusted by 136.73 crore (1367.30 million) to reflect expected rental adjustments on AMSHL hospital site with lease renewal in progress.
The number that misleads

AHEL's consolidated EBITDA margin (14.94% derived from 3769.30 crore EBITDA on 25228.50 crore operating revenues) is highly misleading. It blends three fundamentally distinct business models with disparate economics: high-margin brick-and-mortar hospitals (25.5% EBITDA margins), a stable offline pharmacy distribution channel with high capital efficiency (57.3% ROCE), and a highly dilutive, venture-style digital health platform (Apollo 24/7) that has been incurring heavy cash losses.

Read from Auditor reportEarnings callGuidanceRelated partyShareholding
Read the detail ↓

What Apollo Hospitals Enterprise actually does from the filings

Apollo Hospitals Enterprise Limited (AHEL) operates India's largest integrated healthcare network, spanning tertiary/quaternary hospitals, diagnostics, primary care clinics, and pharmacies. The company sells clinical treatments, surgical consultations, preventative diagnostics, and pharmaceutical medicines to retail patients, corporate groups, and insurance policyholders. Patients choose Apollo because of its clinical brand equity, advanced robotic surgeries, high success rates, and national clinical team. The company leverages its multi-channel 'One Apollo' ecosystem to engage patients continuously across physical and digital platforms. This seamless continuum of care creates high patient retention and strong recurring healthcare revenues across India.

How the money is actually made

Inpatient and outpatient medical treatments, offline pharmacy distribution, diagnostics, and digital healthcare platform transactional commission fees.

Where the edge is

Clinical leadership in high-acuity specialties (such as oncology and cardiac sciences) paired with India's largest omnichannel retail pharmacy footprint (~7,289 stores) and a low-CAC digital platform.

Operating KPIs — the physical business behind the numbers (13)
Inpatient Discharges 628,998 FY2026
Average Revenue Per Patient (ARPP) 178,434 FY2026
Average Length of Stay (ALOS) 3.17 FY2026
Hospitals Occupancy Rate 67.0 FY2026
Operating Beds Count 8,131 FY2026
Capacity Bed Count 10,970 FY2026
Physical Pharmacy Count 7,289 FY2026
Private Label Sales share 15.2 FY2026
Average Revenue Per Patient (ARPP) Q4 FY26 187,208 Mar 2026
Average Length of Stay (ALOS) Q4 FY26 3.19 Mar 2026
Group-wide Occupancy Rate Q4 FY26 68.0 Mar 2026
Registered Users on Apollo 24/7 47,000,000 FY2026
Diagnostics Centres footprint 2,501 FY2026

Screener puts these behind a paywall. They are disclosed in the annual report and investor presentation, so they are free here, with the source printed.

  • Healthcare services
  • Retail health and diagnostics
  • Digital health and pharmacy distribution

The read

Apollo Hospitals (AHEL) is navigating a massive strategic and structural transformation. Its core hospital segment continues to generate solid cash flows (2855.70 crore consolidated CFO in FY2026) with healthy 25.5% operating margins, which are actively being reinvested in a massive 8,000-bed network expansion program. However, this growth is temporarily masked by pre-operating EBITDA drags from recently soft-commissioned hospital beds and the incubation losses of its digital platform, Apollo 24/7. To unlock shareholder value, management is executing a complex series of transactions, including buying out IFC's minority stake in Apollo Health and Lifestyle Limited (AHLL) for 1250.00 crore, combining its capital-intensive Cradle/Fertility business with Cloudnine at an attractive 1550.00 crore valuation (35x EBITDA), and prepping the consolidated HealthCo vertical for a listing as Apollo Healthtech Limited by Q4 FY27. This demerger should decouple the highly profitable brick-and-mortar hospital operations from the high-growth, cash-burning digital and retail pharmacy assets.

Why the headline number misleads here

AHEL's consolidated EBITDA margin (14.94% derived from 3769.30 crore EBITDA on 25228.50 crore operating revenues) is highly misleading. It blends three fundamentally distinct business models with disparate economics: high-margin brick-and-mortar hospitals (25.5% EBITDA margins), a stable offline pharmacy distribution channel with high capital efficiency (57.3% ROCE), and a highly dilutive, venture-style digital health platform (Apollo 24/7) that has been incurring heavy cash losses. Instead of evaluating AHEL on blended consolidated margins, investors must look at the Segment-wise Capital Employed, PBIT margins, and segment ROCE. Specifically, isolating the mature Healthcare Services segment (which generated 2430.30 crore in segment PBIT on 12750.10 crore revenue) reveals a highly profitable, self-funding core, while tracking the declining digital cash losses (which fell from 80.00 crore in Q4 FY25 to 16.00 crore in Q4 FY26) provides the real trajectory of the company's operating leverage.

What matters most

The execution timeline and structural pricing of the demerger and listing of Apollo Healthtech Limited by Q4 FY27, alongside the successful operationalization and breakeven of the planned 1,000 bed brownfield/greenfield additions in FY2027. Because the high-margin offline pharmacy business (57.3% ROCE) is currently bundled with the cash-consuming digital platform within Apollo HealthCo, the upcoming demerger will reveal the true underlying profitability of each segment, allowing independent capital allocation and rerating of the pure-play hospital business.

What would change the picture

A delay in the demerger timeline beyond Q4 FY27, or pre-operating losses from the new hospital beds exceeding the guided 150.00 crore cap in FY2027, which would indicate operational execution bottlenecks. Conversely, an acceleration in the breakeven timeline of the digital platform (from the guided Q1 FY2027 target) or exceeding the 6.5%-7.0% EBITDA exit margins for HealthCo in FY2027 would significantly de-risk the projection.

Price in context split-adjusted

1M
-2.1%
6M
+13.3%
1Y
+12.2%
12.2% CAGR
3Y
+80.9%
21.8% CAGR
5Y
+74.6%
11.8% CAGR
From high
-2.3%
worst -38%
Close 50-DMA 200-DMA own P/E band (median ±1σ)
Trading at 79.7x against its own 10-year median of 72.1x0.3σ above its usual range. This compares the company with its own history, not with other companies.
1PROPOSED NCD ISSUANCE ₹50 cr2025-08

Numbered markers are corporate actions and, once the filings are read, capital and governance events. Prices are split-adjusted so the series is continuous.

What you must understand
warnBalance-Sheet Cash Depletion on IFC Buyout
Substantially reduces immediate liquidity and cash buffers on AHEL's standalone balance sheet just as the 1980.00 crore growth capex cycle for FY2027 begins to accelerate.
a92ca15b-cc03-4f67-84fa-499d2270f3ae.pdf / transcript-of-apollo-hospitals---q4-fy26-earnings-call.pdf · Note 244 / p.10
Full read
verified Large, non-recurring cash outflow of 1250.00 crore has materially altered sequential net debt metrics and reduced standalone liquidity.
warnPre-Operating EBITDA Drag from Staggered Launches
These losses drag down immediate group margins and cash flows, masking the steady-state 25.5% margins of established hospitals during the critical bed ramp-up phase.
transcript-of-apollo-hospitals---q4-fy26-earnings-call.pdf · p.4, p.6
Full read
verified Pre-operating drag is substantial relative to segment profit and represents a lingering headwind during the 12-18 month commercialization cycle.
warnAMSHL Land Lease Non-Renewal Risk
Operating a flagship clinical facility in Kolkata on an expired lease under active renegotiation poses long-term structural and regulatory uncertainties with potential cost escalations.
a92ca15b-cc03-4f67-84fa-499d2270f3ae.pdf · Note 244 (p.13)
Full read
verified Critical operating land lease is expired/due and pending final renewal, introducing localized operational and regulatory risk.
warnSignificant Subsidiary Audit Deficit
Presents a structural information-asymmetry risk for consolidated accounts, as a notable portion of subsidiary earnings is consolidated based solely on other auditors' reports.
f9b40997-8116-48ba-949a-ca2e7775e3c2.pdf · Consolidated Independent Auditor's Report
Full read
verified High absolute number of unreviewed subsidiaries consolidates significant revenues and earnings without direct overview of the principal auditor.
warnCARO Localized Control Exceptions
Highlights persistent localized internal control weaknesses and financial viability issues across non-core and incubating subsidiary platforms.
f9b40997-8116-48ba-949a-ca2e7775e3c2.pdf · Consolidated Independent Auditor's Report (CARO Annexure)
Full read
verified Widespread exceptions in CARO annexures point to localized compliance and internal audit gaps across a diverse portfolio.
noteLarge Outstanding Contingent Liability Exposure
Represents a high volume of outstanding legal and direct tax disputes under active appeal that pose a risk of material future cash drains if decided adversely.
f9b40997-8116-48ba-949a-ca2e7775e3c2.pdf · Consolidated Note on Contingent Liabilities
Full read
verified

What they promised, and what happened

Consolidated EBITDA Target for Executive Bonus
Said100% target baseline Nomination and Remuneration Committee, 2025-05-27
Happened94% of target achieved
Partial
Revenue Target for Executive Bonus
Said100% target baseline Nomination and Remuneration Committee, 2025-05-27
Happened98% of target achieved
Partial
Net Promoter Score (Patient Satisfaction)
Said71 Nomination and Remuneration Committee, 2025-05-27
Happened74 (104% achievement)
Delivered
ESG Measures (Energy Efficiency and Gender Parity)
Said10% energy reduction & 56% Gender Parity Nomination and Remuneration Committee, 2025-05-27
Happened10% energy reduction achieved and 56% Gender Parity achieved (100% achievement)
Delivered
Apollo HealthCo FY26 Revenue
SaidOn track for consistent growth Management, 2025-05-21
HappenedRevenues reached INR 10,808 crore (19.0% YoY growth)
Delivered
Apollo HealthCo FY26 Profitability
SaidTargeting first full year of profitability Suneeta Reddy, 2025-05-21
HappenedAchieved first full year of profitability with PAT of INR 324 crore
Delivered

On the record, not yet due

Healthcare Services (Hospitals) Revenue Growth Mid-teen growth in FY27 A. Krishnan · 2026-05-21 · by FY2027
Established hospitals EBITDA margin improvement Improve by at least 100 basis points or sustain sustainably get to 25.5% A. Krishnan · 2026-05-21 · by FY2027
Healthcare Services (Hospitals) EBITDA Loss from New Units INR 150 crore is what we would for now look at for the overall hospitals business A. Krishnan · 2026-05-21 · by FY2027
Apollo HealthCo Annualized Revenue Run Rate INR 25,000 crore of annualized revenue by Q4 of FY27 A. Krishnan / Madhivanan B. · 2026-05-21 · by Q4 FY27
Apollo HealthCo EBITDA Margin (Exit Rate) 6.5% to 7% EBITDA margin by Q4 of FY27 A. Krishnan / Madhivanan B. · 2026-05-21 · by Q4 FY27
Apollo HealthCo GMV/Revenue Growth Confidently growing at 21% Madhivanan B. · 2026-05-21 · by FY2027
Hospital Bed Expansion (FY27) Add 1,000 beds in FY27 alone and 8,000 new beds by FY31 Suneeta Reddy / A. Krishnan · 2026-05-21 · by FY2027
Apollo Cradle Transaction Completion Formal commercial transaction completion scheduled between August and September Sriram Iyer / A. Krishnan · 2026-05-21 · by Q2 FY27

Every line is dated and attributed, so the next results can be checked against it.

Reading the annual report

Where they say they are going
Apollo has launched an aggressive network expansion plan aiming to add 1,000 beds in FY27 alone and 8,000 new beds by FY31. This long-term program is backed by a planned capital investment of approximately ₹8,300.00 crore to commission over 4,300 beds in key metro markets. In the immediate next two quarters, AHEL is poised to commission two major new hospitals in Sarjapur and Gurugram, which will expand metro capacity by nearly 25.0%.
What they promised before, and what happened
In FY26, Apollo successfully operationalized 185 beds as part of the initial phase of its four new hospitals in Pune, Kolkata, Hyderabad, and Delhi NCR, out of a total potential capacity of 855 beds. The remaining 670 beds are scheduled for phased commissioning over the next 12 to 18 months as operations ramp up. Concurrently, established hospitals maintained strong momentum, achieving an occupancy rate of 68.0% in Q4 FY26, and consolidated revenue grew 16.0% to ₹25,228.50 crore in FY26.
Where the money actually went
During FY26, Apollo invested ₹1,962.00 crore in capital expenditure across its hospitals to support future growth. Alongside this, the group declared an interim dividend of ₹10.00 per share (aggregating to ₹143.79 crore) in February 2026 and recommended a final dividend of ₹10.00 per share, making a total payout of ₹287.60 crore. To consolidate ownership before its upcoming demerger, Apollo also deployed ₹1,250.00 crore of cash reserves in Q4 FY26 to buy out IFC's 30.58% minority stake in AHLL.
What they are becoming less dependent on
On May 20, 2026, Apollo's Board approved combining its Apollo Cradle and Fertility businesses under AHLL with Kids Clinic India (Cloudnine). The strategic transaction values AHLL's Mother & Child and Fertility businesses at ₹1,550.00 crore, comprised of ₹765.00 crore cash consideration and a 9.9% equity stake in Kids Clinic India Limited (Cloudnine) valued at ₹785.00 crore. This allows Apollo to focus resources on its high-growth diagnostic laboratories and primary clinics.
The part most readers miss
Casual readers overlook that Apollo's offline pharmacy business generates a staggering 57.3% ROCE as of March 2026, which subsidizes its digital health tech incubation. While retail investors focus on digital GMV growth, they miss that digital cash losses have declined sharply from ₹80.00 crore in Q4 FY25 to ₹16.00 crore in Q4 FY26. Under the hood, Apollo is progressing a demerger of this combined HealthCo vertical into Apollo Healthtech Limited, targeting a public listing by Q4 FY27.

Forensic modelscomputed from the filed statements

Every score below is calculated here from the reported numbers — none of it is asserted. Open the notebook at the foot of the section to see each formula with this company's figures in it.

Altman Z″

6.51 Safe

Distress model for emerging markets. Above 2.6 is safe, below 1.1 is the distress zone.

What is this, and how do I read it?

Altman Z″ — distress model — Edward Altman, NYU, 1968; the Z″ variant was published in 1995 for emerging markets and non-manufacturers.

A single score built from four balance-sheet ratios that, together, separated companies that later went bankrupt from those that did not. Altman tested it on manufacturers; the Z″ version drops the sales-to-assets term, which made industrial firms look better than service businesses.

X1 · Working capital ÷ total assets
Short-term liquidity. Negative means current liabilities exceed current assets — the company owes more within a year than it holds.
X2 · Retained earnings ÷ total assets
Cumulative profitability. A young or serially loss-making company scores low here regardless of this year.
X3 · EBIT ÷ total assets
Operating productivity of the asset base, before financing and tax.
X4 · Net worth ÷ total liabilities
How far assets can fall before liabilities exceed them.

How to read itAbove 2.6 is the safe zone. Between 1.1 and 2.6 is grey. Below 1.1 is the distress zone. The score is a screen, not a prediction — it tells you which balance sheets deserve a second look.

Where it failsNot meaningful for banks, NBFCs or insurers, whose balance sheets are structurally different. Also unreliable for asset-light businesses, which carry few assets by design, and for holding companies whose value sits in unconsolidated stakes.

Piotroski F

8 / 9
  • Profitable this year
  • Operating cash positive
  • Return on assets improved
  • Cash exceeds profit
  • Leverage reduced
  • Liquidity improved
  • No share dilution
  • Margin improved
  • Assets working harder
What is this, and how do I read it?

Piotroski F-Score — fundamental momentum — Joseph Piotroski, University of Chicago, 2000, in a study of whether accounting signals could improve returns among cheap stocks.

Nine yes-or-no tests across profitability, leverage and operating efficiency. Each pass scores one. It asks a narrow question: is this business getting better or worse on its own terms, year over year?

Profitability (4 tests)
Positive profit, positive operating cash, improving return on assets, and cash exceeding profit. The last is the quality test — profit that outruns cash is the one to question.
Leverage and liquidity (3 tests)
Falling debt, improving current ratio, no new shares issued. Growth funded by dilution scores zero here.
Operating efficiency (2 tests)
Improving margin and improving asset turnover.

How to read it7 or more suggests improving fundamentals; 3 or fewer suggests deterioration. It measures direction, not quality — a weak company improving can score higher than a strong one holding steady.

Where it failsA single year of comparison, so one unusual year distorts it. Says nothing about valuation, competitive position or management. Piotroski designed it to rank already-cheap stocks, not to judge a company in isolation.

Beneish M

-2.10 Below threshold
DSRI 0.998GMI 0.928AQI 2.382SGI 1.158DEPI 0.679SGAI 0.991LVGI 1.147TATA -0.041
What is this, and how do I read it?

Beneish M-Score — earnings manipulation — Messod Beneish, Indiana University, 1999. Best known for the Cornell students who flagged Enron with it a year before the collapse.

Eight ratios comparing this year with last, weighted into one score. It does not detect fraud. It detects the accounting patterns that tend to accompany managed earnings — receivables outrunning sales, margins falling while the business grows, assets shifting into categories that are harder to verify.

DSRI · Days Sales in Receivables Index
Receivables against sales, this year versus last. Above 1 means the company is collecting more slowly — sales may be being recognised before cash is likely.
GMI · Gross Margin Index
Last year's margin divided by this year's. Above 1 means margins deteriorated, which raises the incentive to manage the numbers.
AQI · Asset Quality Index
The share of assets that are neither current nor fixed — intangibles, deferred costs, "other". Above 1 means more of the balance sheet has moved into items whose value rests on judgement.
SGI · Sales Growth Index
Growth itself is not manipulation, but fast-growing companies face more pressure to sustain the trajectory.
DEPI · Depreciation Index
Above 1 means the depreciation rate slowed — assets are being written off more slowly, which flatters profit.
SGAI · Selling, General & Administrative Index
Overheads against sales. A disproportionate rise signals loss of control.
LVGI · Leverage Index
Rising leverage increases the pressure to meet covenants.
TATA · Total Accruals to Total Assets
The heaviest weight in the model. Profit not backed by cash, scaled by assets.

How to read itAbove −1.78 is the threshold at which the model classifies a company as a likely manipulator. That threshold produces false positives — fast growers and companies mid-acquisition often cross it innocently. Treat it as a prompt to read the notes, never as an accusation.

Where it failsNeeds two comparable years. Meaningless after a large acquisition, demerger or accounting-standard change, when the year-over-year ratios compare different businesses. Not applicable to banks or insurers.

Cash vs profit

1.47× 2-year cumulative

Accruals are -4.3% of assets. Free cash flow negative in 0 of 2 years.

DuPont — return on equity FY2026

Net margin7.7%× Asset turnover1.14×× Leverage2.34×= ROE20.5%
What is this, and how do I read it?

DuPont decomposition — Devised inside the DuPont Corporation in the 1920s and still the standard way to read a return on equity.

Splits return on equity into its three sources, so the same headline number can be traced to very different businesses.

Net margin
What the company keeps from each rupee of sales. High margin points to pricing power or a genuine cost advantage.
Asset turnover
Sales generated per rupee of assets. High turnover points to efficiency — a retailer earns this way, a utility never will.
Leverage (equity multiplier)
Assets divided by equity. This multiplies whatever the first two produce, in both directions.

How to read itA 20% ROE built on margin and turnover is a different proposition from a 20% ROE built on 3× leverage. The first survives a downturn; the second amplifies it.

Where it failsA single year. Negative equity makes it meaningless. Leverage is structural for lenders, so the third term carries no signal there.

Leverage & coverage FY2026

Debt / equity0.60×
Interest coverage6.92×
Net debt / EBITDA1.29×
The formula notebook — every number above, worked out
Cash vs profit cumulative operating cash flow ÷ cumulative net profit ₹4,992 cr ÷ ₹3,388 cr, over 2 years 1.47× Above 1.0 means cash exceeds reported profit — the healthier reading.
Accruals (Sloan) (net profit − operating cash flow) ÷ average total assets (₹1,942 − ₹2,856) cr ÷ average assets -4.3% Negative means cash exceeded profit — the healthier reading. Positive above ~10% is where accruals start to dominate earnings.
DuPont — return on equity net margin × asset turnover × leverage 7.7% × 1.14 × 2.34 20.5% Splits ROE into whether returns come from operations or from borrowing.
Altman Z″ — distress zone 3.25 + 6.56·(WC/TA) + 3.26·(RE/TA) + 6.72·(EBIT/TA) + 1.05·(NW/TL) 3.25 + 6.56×0.019 + 3.26×0.424 + 6.72×0.14 + 1.05×0.776 6.51 — Safe Above 2.6 safe · 1.1 to 2.6 grey · below 1.1 distress. The emerging-market variant.
Beneish M — earnings manipulation −4.84 + 0.920·DSRI + 0.528·GMI + 0.404·AQI + 0.892·SGI + 0.115·DEPI − 0.172·SGAI + 4.679·TATA − 0.327·LVGI DSRI 0.998 · GMI 0.928 · AQI 2.382 · SGI 1.158 · DEPI 0.679 · SGAI 0.991 · TATA -0.041 · LVGI 1.147 -2.10 Above −1.78 is the threshold at which the model flags a company as a likely manipulator.
Interest coverage EBIT ÷ finance cost ₹3,111 cr ÷ ₹450 cr 6.92× How many times operating profit covers the interest bill.
Debt to equity borrowings ÷ net worth ₹5,659 cr ÷ ₹9,480 cr 0.60× Read against the sector — infrastructure carries more than software.

Going deepersame statements, harder questions

Montier C-Score

1 / 6 flags raised
  • Profit and cash flow diverging
  • Receivables growing faster than sales
  • Inventory building against sales
  • Other assets rising as a share of the balance sheet
  • Depreciation falling against fixed assets
  • Assets growing unusually fast

Six conditions that tend to appear together when earnings are being managed. A flag is a question, not a verdict.

What is this, and how do I read it?

Montier C-Score — the cooking score — James Montier, then at Dresdner Kleinwort, 2008, as a deliberately simpler companion to Beneish.

Six binary flags, each a condition that appears when earnings are being flattered. Montier's argument was that you do not need a weighted regression — the conditions tend to cluster, and counting them is enough.

Profit and cash diverging
Net income growing faster than operating cash flow. The single most reliable warning in accounting.
Receivables growing faster than sales
Revenue recognised ahead of collection.
Inventory building against sales
Production outrunning demand, with the write-down still to come.
Other assets rising as a share of the balance sheet
Value migrating into items that are difficult to verify.
Depreciation slowing against fixed assets
Useful lives extended, which lifts reported profit without any operating change.
Assets growing unusually fast
Above roughly 25% a year, often through acquisition, which resets the comparative base and obscures the underlying trend.

How to read it4 or more flags warrants a careful read of the notes. 0 or 1 is unremarkable. Each flag is a question — several together are a pattern.

Where it failsA company mid-expansion trips several flags legitimately: inventory builds ahead of a launch, assets grow with a new plant. Read alongside what the business is actually doing.

Return on invested capital FY2026

ROIC16.3%
Capital employed₹14,327 cr

NOPAT over equity plus debt less cash, at a notional 25% tax. Incremental ROIC is the return on money put in since then — the number that decides whether growth creates value or consumes it.

What is this, and how do I read it?

Return on invested capital, and incremental ROIC — Standard in corporate finance; the incremental form was popularised by Michael Mauboussin as the test of whether growth creates value.

ROIC measures what the business earns on all the capital it employs — equity plus debt, less cash. Incremental ROIC asks a sharper question: what has it earned on the money put in since a chosen year?

NOPAT
Operating profit after a notional tax charge, so the figure is independent of how the company is financed. We use 25%.
Invested capital
Equity plus borrowings less cash — the money actually at work.
Incremental ROIC
Change in NOPAT divided by change in invested capital. If it sits below the cost of capital, growth is destroying value however fast revenue rises.

How to read itROIC comfortably above the cost of capital — call it 11–13% in India — means growth compounds. Below it, growth consumes. Incremental below headline means recent investment is earning less than the legacy business.

Where it failsDistorted in the year of a large acquisition. Understated for companies mid-build, where capital is deployed but capacity has not yet been commissioned — an incubator will look poor until it does not.

Earnings quality ladder FY2026

Cash ÷ EBITDA0.76×
Cash ÷ profit1.47×
Free cash ÷ profit0.46×

Read downward. Cash can cover EBITDA and still not survive capex — the third rung is where a capital-hungry business shows itself.

What is this, and how do I read it?

The earnings quality ladder — Not a named model — the standard sequence an analyst walks when testing whether reported profit is real.

Three ratios read in order, each stricter than the last.

Cash ÷ EBITDA
Does operating profit arrive as cash? Below 0.8 points to working capital absorbing it.
Cash ÷ profit
Does bottom-line profit arrive as cash? Below 1.0 persistently is the classic warning.
Free cash ÷ profit
Does anything survive capex? This is where capital-hungry businesses reveal themselves — a company can pass the first two and still never generate spendable cash.

How to read itRead downward. Each rung failing where the one above passed tells you exactly where the cash is going.

Where it failsA single year of heavy capex depresses the third rung legitimately. Judge it across a cycle.

What the price implies

36.7% free cash flow growth, every year for ten years

The growth rate that makes today's market value equal the discounted cash flows, at a 11.5% discount rate and 4.0% terminal growth. Not a forecast — the arithmetic of what is already in the price. Compare it with what the business has actually delivered.

What is this, and how do I read it?

Reverse DCF — the growth already in the price — A standard inversion of discounted cash flow, used to avoid the forecasting problem entirely.

Instead of forecasting cash flows and deriving a value, it takes today's market value as given and solves for the growth rate that would justify it. The output is not a view — it is the arithmetic of what the market is currently assuming.

Discount rate
The return required for the risk taken. We use 11.5%, roughly the long-run cost of equity in India.
Terminal growth
Growth beyond the explicit ten years. We use 4%, near long-run nominal GDP.
The output
The free-cash-flow growth rate, every year for a decade, that makes the discounted total equal today's market value.

How to read itCompare it with what the business has actually delivered. A price implying 30% a year against a decade of 15% is a demanding assumption; the reverse is a modest one.

Where it failsUseless when free cash flow is negative or unusually depressed, which is common mid-capex. Highly sensitive to the discount rate — a point either way moves the answer materially.

Cost of debt FY2026

Interest ÷ average borrowings8.22%
Average borrowings₹5,467 cr

Against a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%.

What is this, and how do I read it?

Cost of debt — Interest expense over average borrowings — the effective rate the company actually pays.

What the lenders charge, which is a market verdict on credit quality that no rating agency delay affects.

Well below the policy rate
Suggests interest is being capitalised into assets rather than expensed, or that funding comes from related parties on non-market terms.
Near the policy rate plus a normal spread
Ordinary bank funding. Nothing to explain.
Well above
Lenders are pricing risk the equity market may not yet be.

How to read itAgainst a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%. Read the direction over years as much as the level.

Where it failsUnderstated where a large share of interest is capitalised into projects under construction. Not meaningful for lenders, where interest is cost of goods.

Published screening frameworksrules applied, not opinions quoted

Each framework below is a set of stated, mechanical criteria from published work, run against this company's own filed numbers. Passing or failing a screen is not a verdict — different frameworks disagree by design, and that disagreement is itself informative.

Graham — defensive investor

1 / 4
  • Current ratio above 2 1.06×
  • Debt below net worth ₹5,659 cr vs ₹9,480 cr
  • P/E below 15 59.7×
  • P/E × P/B below 22.5 800.5

Benjamin Graham's stated criteria for a defensive stock, applied to the filed numbers. A company failing several is not disqualified — Graham designed these to be deliberately strict.

Greenblatt — magic formula

1 / 2
  • Return on capital above 20% 20.5%
  • Earnings yield above 8% 1.7%

Two ratios only: what the business earns on its capital, and what you pay for those earnings. Designed to be ranked across a universe rather than read in isolation.

O'Neil — CAN SLIM growth tests

3 / 4
  • Annual earnings growth above 25% 34%
  • Revenue growth above 20% 16%
  • Return on equity above 17% 20.5%
  • Share count not expanding equity capital ₹72 cr

The fundamental half of William O'Neil's framework. The market and leadership components are judgement calls and are not scored here.

Quality — compounder tests

1 / 2
  • Interest covered more than 4× 6.92×
  • Debt below half of equity 0.60×

The characteristics long-term holders commonly look for: cash-backed earnings, high returns on capital, and debt that never forces a decision.

Growth & valuation workspace

Set your own assumptions and watch the numbers move. A scenario calculator — the outputs are the arithmetic of your inputs.

User-driven scenario tool. Implied value and CAGR follow only from the assumptions you set — not a FinMinutes forecast, recommendation, or target price.

Valuation & quality

One canonical set of figures — the same numbers used everywhere else on this page and on the screener.

What you payHow the price compares with earnings, book and sales.
P/E (TTM)
59.7x
P/B
13.40x
P/S
4.81x
PEG
1.83
Dividend yield
0.23%
What it earnsMargins and the return generated on the capital employed.
Operating margin
11.7%
Net margin
8.1%
Return on equity
18.1%
How it is fundedLeverage and what is returned to shareholders.
Debt / equity
0.90
moderate
Payout ratio
6.9%
Book value / share
₹658.3
Return on equity of 18.1% is built on a 8.1% net margin and debt of 0.90x equity. The full DuPont breakdown sits in the forensic models above.

Ownership & Skin in the Game

How the register has moved over recent quarters — the direction matters more than the level.

Promoter ― 0.00
Sep '2528.02% Dec '2528.02% Mar '2628.02% Jun '2628.02%

Promoter held steady from 28.02% to 28.02% across these quarters.

FII ▼ 2.71
Sep '2544.20% Dec '2543.54% Mar '2642.62% Jun '2641.49%

FII trimmed from 44.20% to 41.49% across these quarters.

MF ▲ 0.85
Sep '2516.48% Dec '2516.75% Mar '2616.65% Jun '2617.33%

MF rose from 16.48% to 17.33% across these quarters.

Other ▲ 1.86
Sep '2511.30% Dec '2511.69% Mar '2612.71% Jun '2613.16%

Other rose from 11.30% to 13.16% across these quarters.

Skin in the game

A holding percentage says who controls the company. This says whether the promoter has been putting money in or taking it out.

Money in₹0 cr
Money out₹72 cr
Net−₹72 cr
OUT Dividends paid PCR Investments Ltd and other Promoter Group members FY2026 ₹15 cr promoter share of ₹81 cr paid · 18.93%
OUT Remuneration of Promoter Key Management Personnel Promoter Executive Directors FY2026 ₹57 cr
Why the holding percentage moved

PROPOSED NCD ISSUANCE ₹50 cr · 2025-08-29
Augment long term resources for financing ongoing capital expenditure and expansion activities

A fall in promoter percentage after a fresh issue is dilution, not selling. Selling would show in the ledger above.

Named holders

HolderTypeStakePledgedAs of
PCR Investments Ltd Promoter 18.93% 2026-03-31
Smt. Suneeta Reddy Promoter group 2.04% 2026-03-31
Smt. Sangita Reddy Promoter group 1.69% 2026-03-31
Smt. Shobana Kamineni Promoter group 1.56% 2026-03-31
Mr. K Vishweshwar Reddy Promoter group 1.10% 2026-03-31
Government of Singapore Fii 2.10% 2026-03-31
Axis Mutual Fund Mutual fund 1.86% 2026-03-31
SBI Nifty 50 ETF Mutual fund 1.86% 2026-03-31
Mirae Asset ELSS Tax Saver Fund Mutual fund 1.81% 2026-03-31
Life Insurance Corporation of India Insurance 1.66% 2026-03-31
Government Pension Fund Global Fii 1.65% 2026-03-31
Aditya Birla Sun Life Trustee Private Limited Mutual fund 1.48% 2026-03-31
ICICI Prudential Balanced Advantage Fund Mutual fund 1.32% 2026-03-31
Nippon Life India Trustee Ltd Mutual fund 1.28% 2026-03-31
HDFC Trustee Company Limited Mutual fund 1.18% 2026-03-31

Hospital Vitalsthe numbers a P&L hides

Operating metrics disclosed in the business review and MD&A. These, not margins, are what the business is actually run on.

Capacity Beds 10970beds
FY2026 ▲ 783 vs FY2025

Total capacity bed count across the network (p.20, Operational Highlights)

Operating Beds 8131beds
FY2026 ▲ 106 vs FY2025

Total operational beds across the network, excluding AHLL & managed beds (p.20, Operational Highlights)

Hospitals Occupancy Rate 67%
FY2026 ▼ 1.0 vs FY2025

Overall occupancy rate of hospitals (excluding AHLL & managed beds) (p.16, Operational Summary)

Average Revenue Per Patient (ARPP) 178434
FY2026 ▲ 15,532 vs FY2025

Average Revenue Per Patient, used as the primary realization metric in filings (p.16, Operational Summary)

Average Length of Stay (ALOS) 3.17days
FY2026 ▼ 0.2 vs FY2025

Average length of hospital stay (p.16, Operational Summary)

Immediate Bed Expansion Pipeline 1000beds
FY2027 ▲ 815 vs FY2026

Bed additions planned for FY2027 (H1) vs actual operationalized beds in FY2026 (p.56, Growth Horizon)

Payer Mix - Standalone Credit Share derived 53.2%
FY2026 ▲ 0.1 vs FY2025

Calculated share of standalone healthcare services revenue paid via credit/insurance (₹4961.60 crore Credit vs total ₹9326.20 crore) (p.164, Note 244)

Inpatient Volumes (Discharges) 628998discharges
FY2026 ▲ 24,748 vs FY2025

Total inpatient discharges across hospitals during the year (p.16, Operational Summary)

Inpatient Share of Treatment Revenue (Standalone) derived 75.56%
FY2026 ▲ 2.6 vs FY2025

Calculated share of inpatient revenue out of total standalone treatment revenue (₹6892.30 crore Inpatient vs ₹2229.30 crore Outpatient) (p.164, Note 244)

Trends

The shape of the business over time (annual) — read the direction, not the single print.

Revenue (₹ cr)
Dec 20256.5kFY202521.8kFY202625.2kMar 20266.6k
Net profit (₹ cr)
Dec 2025502FY20251.4kFY20261.9kMar 2026529
EBITDA margin (%)
Dec 202514.8%FY202513.7%FY202614.8%Mar 202615.2%

Annual Profit & Loss ₹ cr

LineFY2025FY2026
Revenue from operations21,79425,229
Other income200192
Total income21,99425,420
EBITDA3,0223,769
Depreciation758876
Finance cost459450
Profit before tax2,0392,661
Net profit (owners)1,4461,942
EPS (₹)100.56135.04

Exceptional items, total income and EBITDA are read from the filed statements.

Quarterly Financials ₹ cr

MetricDec 2025Mar 2026
Revenue
Expenses
Other Income5344
Depreciation219224
Profit before tax682722
Net Profit
EPS

Balance Sheet ₹ cr, annual

ItemFY2025FY2026
Equity Capital7272
Reserves8,1409,408
Borrowings5,2755,659
Fixed Assets
CWIP111
Investments2,2631,922
Total Assets20,65722,197

Cash Flow ₹ cr

LineFY2025FY2026
Cash from operations2,1362,856
Capital expenditure1,7131,962
Cash from investing-3,383-2,148
Cash from financing1,319-478

Cash from operations is the number profit has to answer to. Free cash flow is what remains after the business pays for its own growth.

From the filings, calls & disclosures

The part no one reads — pulled from the annual report, auditor's report, concall and deck. This is the moat.

Risk register & disputes (4)
  • The Company is contingently liable for claims not acknowledged as debt totaling Standalone 503.20 crore and Consolidated 819.50 crore as of March 31, 2026.Disputed legal claims filed against the company/group pending before judicial forums.
  • The Company has disputed income tax demands under appeal totaling Standalone 88.70 crore as of March 31, 2026.Disputed direct tax demands under appeal with various income tax appellate authorities.
  • The Company recognized impairment of 39.30 crore in the value of its equity investments in Apollo Lavasa Health Corporation Limited and Stemcyte India Therapeutics Private Limited in Standalone accounts.Impairment of long-term strategic investments due to ongoing cash losses and erosion of net asset values.
  • The flagship hospital site land lease of AMSHL is expired and renewal is actively in progress with estimated rental adjustment of 136.73 crore adjusted in ROU assets.Flagship operating hospital site lease is under renewal with municipal government.
Audit & governance
Opinionunmodified
AuditorDeloitte Haskins & Sells LLP
EmphasisNote 5(iii) [or Note 8] regarding proceedings initiated against the subsidiary, Imperial Hospital and Research Centre Limited, by the Government of Karnataka alleging non-compliance with certain conditions associated with land allotment.
Guidance & forward view
Healthcare Services (Hospitals) Revenue GrowthMid-teen growth in FY27 FY2027
Established hospitals EBITDA margin improvementImprove by at least 100 basis points or sustain sustainably get to 25.5% FY2027
Healthcare Services (Hospitals) EBITDA Loss from New UnitsINR 150 crore is what we would for now look at for the overall hospitals business FY2027
Apollo HealthCo Annualized Revenue Run RateINR 25,000 crore of annualized revenue by Q4 of FY27 Q4 FY27
Apollo HealthCo EBITDA Margin (Exit Rate)6.5% to 7% EBITDA margin by Q4 of FY27 Q4 FY27
Apollo HealthCo GMV/Revenue GrowthConfidently growing at 21% FY2027
Hospital Bed Expansion (FY27)Add 1,000 beds in FY27 alone and 8,000 new beds by FY31 FY2027
Apollo Cradle Transaction CompletionFormal commercial transaction completion scheduled between August and September Q2 FY27
Narrative vs numbers
Apollo HealthCo margins are guided to expand to 6.5% to 7.0% in Q4 FY27
plausible
The Mother & Child combination with Cloudnine is an exceptional valuation and strategic outcome
verified
The Chennai/Tamil Nadu hospital cluster has occupancy headroom and does not rely solely on ARPP price revisions
plausible
The projected capital expenditure of 1980.00 crore for FY27 is fully self-funded
verified

The latest earnings call Mar 2026 · 2026-05-21

Apollo Hospitals' Q4 FY26 earnings call marked a major milestone as consolidated annual revenues crossed the ₹25,000 crore threshold to reach ₹25,228.50 crore. Suneeta Reddy highlighted strong operational metrics, with Healthcare Services margins sustaining at 25.5% and Apollo HealthCo achieving its first full year of profitability with PAT of ₹324.00 crore. The demerger and listing of Apollo Healthtech is on track with shareholder meetings convened for June 24, 2026, aiming for a listing by Q4 FY27. Additionally, management outlined their hospital bed additions of 1,000 beds in FY27, budgeted at an EBITDA loss of ₹150.00 crore in FY27 before breaking even in FY28, and detailed the Cloudnine transaction which values their Cradle business at ₹1,550.00 crore.

  • Consolidated annual revenues crossed the ₹25,000 crore milestone, finishing at ₹25,228.50 crore (16.0% YoY growth).
  • Apollo HealthCo reported its first full year of profitability, with digital cash losses declining sharply to ₹16.00 crore in Q4 FY26 from ₹80.00 crore in Q4 FY25.
  • The NCLT-convened shareholder meeting for the Apollo Healthtech demerger is scheduled for June 24, 2026, targeting listing by Q4 FY27.
  • The maternity and fertility care business (Apollo Cradle) is combining with Cloudnine, valuing the business at ₹1,550.00 crore, yielding a ₹765.00 crore cash payout and a 9.9% stake.
  • The hospital bed expansion program is on track to add 1,000 beds in FY27, with ₹150.00 crore in losses budgeted for FY27 before achieving breakeven in FY28.
How the tone changed

Highly confident and optimistic, driven by the achievement of first full-year profitability at Apollo HealthCo, rapid scaling of private label pharmacy products, and consistent 9.0% ARPP growth to ₹1,87,208.

The analyst grilling

Where analysts pressed management, and how they answered.

The tough questions (11)
Are you tracking on to the hospital losses budget of INR 150 crore, and which quarter sees the most hit? Also, is the digital breakeven in Q1 on track?
Hospital losses are tracking at around INR 140 crore, with most occurring in the fourth quarter when all facilities are opened. For digital, we expect to be close to or break even in Q1 itself (concall page 4).
Should we assume established hospital growth improves given low seasonality/Bangladesh impact in FY26, and is there scope for margin expansion beyond 25%-25.5%?
Established hospital occupancy will improve next quarter. There is scope for continued established margin improvement of at least 100 to 125 basis points (INR 100-125 crore impact possible) driven by cost reduction and operating leverage, allowing us to sustain the 25.5% margins (concall page 5).
HealthCo exited FY26 with 4.3% margins. How do we achieve the guided 6.5%-7.0% exit margin for FY27 (about 250 bps improvement)?
The 250 bps margin improvement is primarily driven by digital losses coming down to break even by Q1, further growth in private label sales (reached 15.2% in FY26) which are margin-accretive, and flow-through from overall pharmacy distribution volume growth (concall page 6).
We guide INR 140 crore drag from new hospitals. When does the peak drag occur, and how will bed additions be operationalized?
For the full year, new hospital EBITDA losses are capped at INR 150 crore. While 185 beds are commissioned (like Pune with 75 beds), Kolkata was soft-commissioned, Hyderabad was recently commissioned, and Delhi NCR was soft-commissioned a quarter ago. Peak drag can spike in a quarter before ramping up in Q1-Q2 (concall page 6).
Regarding the Apollo Cradle and fertility transaction, why combination with Cloudnine? Was it noncore or about valuation?
It is a combination of factors. One is valuation, getting INR 1,500 crore enterprise value on Cradle/IVF EBITDA at a multiple of 35x in this market, which is exceptional. Strategically, this allows us to double down our focus and capital on Apollo Primary Care and Diagnostics (concall page 7).
Will our diagnostics and primary clinics continue to carry the Apollo brand name after the Cradle combination?
Yes. Primary clinics and diagnostics will continue to carry the Apollo brand name. Only the Cradle hospitals will carry the Apollo brand for a transition period of 1 year before rebranding completely to Cloudnine (concall page 7).
For new hospitals, what has been your experience onboarding insurance partners, given some peers are facing prolonged negotiations?
Apollo has been very fortunate and highly successful in onboarding insurance companies at our new hospitals, without facing the delays or negotiations that peers have experienced, thanks to our strong existing partnerships (concall page 9).
In the Tamil Nadu cluster, occupancy is already at 68% and volume growth has been tepid. Will ARPP remain the sole growth driver?
No. There is still 6% to 7% headroom for growth from pure asset occupancy across other hospitals in the Chennai region. This will be paired with continuous improvements in ARPP and high-acuity case mix driven by advanced clinical technologies (concall page 10).
Can you provide the operating and free cash flows for the Hospital Services segment for FY26, and is the INR 1,980 crore capex for FY27 already spent?
Consolidated operating cash flow generated before dividend was approximately INR 1,550 crore. Our growth capex is fully funded from internal accruals and liquid balances. The capex for FY27 is budgeted for future quarters and not pre-spent (concall page 10).
On a quarter-on-quarter basis, AHEL moved from net cash to net debt with a sequence difference of almost INR 1,200 crore. What accounts for this besides capex?
In addition to normal project capex, we completed the buyout of IFC's minority stake in AHLL this quarter. This required a payout of INR 1,250 crore which came directly out of the Healthcare Services balance sheet (concall page 10).
Regarding the associated company Indraprastha Medical, there is an ongoing legal case with the Delhi Government. Does it impact our holding?
No. We are quite confident that we will take this to a logical conclusion. The land lease is automatically renewable and the free bed obligations are being fully met by the company. Our shareholding continues unaffected, and there are no plans to acquire the Government's 26% stake (concall page 15).

Money owed, promised and moved inside the group

Contingent liabilities

₹1,236 cr in total across 6 disclosed items — 8.0% of net worth. Individual items answer what; the total answers how exposed. The stated total and the sum of the listed items differ, which usually means they sit on different bases — the larger is shown.

Claims against the Company/Group not acknowledged as debt (Consolidated) ₹820 cr · 8.6% of net worth Pending active dispute
Bank guarantees (Consolidated) ₹140 cr · 1.5% of net worth Outstanding
Income tax demands under appeal (Standalone) ₹88.70 cr · 0.89% of net worth Pending appeal
Letters of comfort issued on behalf of related parties (Standalone) ₹124 cr · 1.3% of net worth Issued to banks
Customs duty disputes (Standalone) ₹49.50 cr · 0.50% of net worth Pending active dispute
Goods and Service Tax (GST) demands under appeal (Standalone) ₹14.70 cr · 0.15% of net worth Pending active dispute

Related-party transactions

₹278 cr transacted — approvals are a ceiling, not a spend.

CounterpartyNatureAmountStatus
Apollo Hospitals Worli LLP Subsidiary Non-current loan outstanding ₹151 cr Transacted
Apollo Health and Lifestyle Limited (AHLL) Subsidiary Current loan outstanding ₹45 cr Transacted
Health Axis Private Limited Subsidiary Current loan outstanding ₹27 cr Transacted
Apollo Healthtech Limited Subsidiary Current loan outstanding ₹1 cr Transacted
Assam Hospitals Limited Subsidiary Acquisition of shares (Preferential Allotment) ₹55 cr Transacted

Scorescomputed here, not asserted

Each score is built from disclosed evidence against a fixed rubric. Open a card to see exactly which tests passed and which did not — a score you cannot audit is worth nothing.

Governance

6.4 / 10 7 of 11 points
How this was scored
  • Unmodified audit opinion — Unmodified
  • CARO remarks contained — 13 entities across 4 clauses
  • Subsidiaries auditor-reviewed — 23% reviewed
  • No going-concern notes — none
  • Board majority independent — 50% independent

Sustainability

7.0 / 10 7 of 10 points
How this was scored
  • Assured reporting — TUV SUD South Asia Private Limited
  • Targets quantified — 4 of 4 targets quantified
  • Scope 3 disclosed — disclosed
  • Capex tied to targets — no capex tied to targets
  • Externally assessed — 2 external assessments

Future readiness

6.3 / 10 5 of 8 points
How this was scored
  • Spend disclosed — no spend disclosed
  • Deployments with outcomes — 5 of 5 with a measurable outcome
  • Visible in operating metrics — shows up in operating metrics

Questions worth asking about Apollo Hospitals Enterprise

Revenue GuidanceWhat is the FY27 revenue growth guidance for AHEL's hospital and digital pharmacy businesses?
A. Krishnan guided that the established hospitals are expected to achieve mid-teens revenue growth in FY27, while Apollo HealthCo is on track to reach a ₹25,000.00 crore annualized revenue run rate by Q4 FY27, up from a pro forma baseline of ₹19,000.00 crore.
Margin SqueezeHow does management plan to expand margins at Apollo HealthCo to offset digital opex pressures?
Sanjiv Gupta stated that Apollo HealthCo exit margins are guided to expand to 6.5% to 7.0% in Q4 FY27 from 4.3% in FY26, driven by higher private label sales (which reached 15.2% in FY26) and digital cash losses breaking even by Q1 FY27, which dropped to ₹16.00 crore in Q4 FY26.
Capex AllocationWhat is the capital expenditure budget for new bed additions in FY27 and how will it be funded?
The group has allocated a growth capex of ₹1,980.00 crore for adding 1,000 beds in FY27, which will be funded out of AHEL's ₹1,550.00 crore in post-dividend operating cash flow generated in FY26 alongside existing liquid balances.
Debt & LeverageWhat led to the ₹1,200.00 crore sequential change from net cash to net debt in Q4 FY26?
AK Krishnan explained that besides regular capital projects, the company deployed ₹1,250.00 crore from its Healthcare Services balance sheet during the quarter to buy out IFC's 30.58% minority stake in Apollo Health and Lifestyle Limited (AHLL), making AHLL a 100.0% subsidiary.
Analyst PushbackHow does management respond to analyst concerns regarding the EBITDA losses from new hospital units?
A. Krishnan clarified that the ₹41.00 crore EBITDA loss from new hospitals in Q4 FY26 is temporary preoperative and soft-commissioning cost, with total losses capped at ₹150.00 crore for FY27 before the entire new bed cluster breaks even in FY28.
Hidden RisksWhat is the status of the land lease for Apollo Multi Specialty Hospitals Limited (AMSHL) and its financial impact?
The land lease renewal is in progress and right-of-use assets/lease liabilities of ₹136.73 crore (₹1,367.30 million) as of March 31, 2026, reflect the estimated obligations arising from the expected rental adjustment under the lease renewal.
Market ShareWhat are the key operating and fulfillment metrics for the Apollo 24/7 digital platform?
Madhivanan B. reported that Apollo 24/7 has reached 4.70 crore registered users, acquiring 200,000 to 220,000 new customers per month, and maintains ₹528.00 crore in Q4 FY26 GMV while same-day delivery stands at 90.0% across physical pharmacy locations.
New VenturesWhat are the exact financial terms and expected completion timeline of the Cradle combination with Cloudnine?
Sriram Iyer confirmed the transaction combines Apollo Cradle and Fertility with Cloudnine at an enterprise value of ₹1,550.00 crore, with AHLL receiving a cash consideration of ₹765.00 crore and a 9.9% stake valued at ₹785.00 crore, and completion scheduled between August and September.
Cash Flow & DividendsWhat were the total dividend payments declared by the board for AHEL in FY26?
The Board declared an interim dividend of ₹10.00 per share in February 2026, aggregating to ₹143.79 crore (₹1,437.85 million), and recommended a final dividend of ₹10.00 per share in May 2026, making a total dividend payout of ₹287.60 crore for the fiscal year.
Pricing PowerHow did volume, case mix, and price revisions contribute to hospital division growth in Q4 FY26?
Hospital division revenue grew 16.0% YoY to ₹3,268.00 crore, driven by a balanced contribution of 7.0% volume growth, 5.0% high-acuity case mix, and 4.0% price revisions, which pushed network average revenue per patient (ARPP) up 9.0% to ₹1,87,208.
Future ReadinessWhat is the specific timeline and final structure for the demerger of the pharmacy and digital healthcare businesses?
The demerger into Apollo Healthtech Limited (part of the HealthCo restructuring) is on track following a scheduled NCLT shareholder vote on June 24, 2026, with the completed regulatory listing of the new entity expected by early Q4 FY27, establishing an independent vehicle to scale HealthCo’s ₹10,808.10 crore pharmacy engine.
DISCLAIMER: FinMinutes is a financial data and analytics platform, not a registered investment adviser. Everything here is for educational and informational purposes. Forensic interpretations are computed from disclosed data and are not recommendations. Do your own due diligence.
Chat on WhatsApp